SEARCH

SEARCH BY CITATION

References

  • 1
    Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science 1965;148:14779.
  • 2
    Hirsch HH. Polyoma and papilloma virus infections after hematopoietic stem cell or solid organ transplantation. In: Bowden P, Ljungman P, Snydman DR, editors. Transplant Infections. 3rd edn. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams & Wilkins, 2010: 46582.
  • 3
    Dalianis T, Hirsch HH. Human polyomaviruses in disease and cancer. Virology 2013;437:6372.
  • 4
    Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971;1:125760.
  • 5
    Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127:46770.
  • 6
    Padgett BL, Rogers CM, Walker DL. JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: Additional biological characteristics and antigenic relationships. Infect Immun 1977;15:65662.
  • 7
    Shishido-Hara Y, Ichinose S, Higuchi K, Hara Y, Yasui K. Major and minor capsid proteins of human polyomavirus JC cooperatively accumulate to nuclear domain 10 for assembly into virions. J Virol 2004;78:9890903.
  • 8
    Gasparovic ML, Gee GV, Atwood WJ. JC virus minor capsid proteins Vp2 and Vp3 are essential for virus propagation. J Virol 2006;80:1085861.
  • 9
    Neu U, Stehle T, Atwood WJ. The Polyomaviridae: contributions of virus structure to our understanding of virus receptors and infectious entry. Virology 2009;384:38999.
  • 10
    Bauman Y, Mandelboim O. MicroRNA based immunoevasion mechanism of human polyomaviruses. RNA Biol 2011;8:5914.
  • 11
    Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. J Virol 1984;51:45869.
  • 12
    Johne R, Buck CB, Allander T, Atwood WJ, Garcea RL, Imperiale MJ, et al. Taxonomical developments in the family Polyomaviridae. Arch Virol 2011;156:162734.
  • 13
    Yogo Y, Kitamura T, Sugimoto C, Ueki T, Aso Y, Hara K, et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol 1990;64:313943.
  • 14
    Sugimoto C, Kitamura T, Guo J, Al-Ahdal MN, Shchelkunov SN, Otova B, et al. Typing of urinary JC virus DNA offers a novel means of tracing human migrations. Proc Natl Acad Sci U S A 1997;94:91916.
  • 15
    Cubitt CL, Cui X, Agostini HT, Nerurkar VR, Scheirich I, Yanagihara R, et al. Predicted amino acid sequences for 100 JCV strains. J Neurovirol 2001;7:33944.
  • 16
    Stoner GL, Jobes DV, Fernandez Cobo M, Agostini HT, Chima SC, Ryschkewitsch CF. JC virus as a marker of human migration to the Americas. Microbes Infect 2000;2:190511.
  • 17
    Agostini HT, Deckhut A, Jobes DV, Girones R, Schlunck G, Prost MG, et al. Genotypes of JC virus in East, Central and Southwest Europe. J Gen Virol 2001;82:1221331.
  • 18
    Sugimoto C, Hasegawa M, Kato A, Zheng HY, Ebihara H, Taguchi F, et al. Evolution of human Polyomavirus JC: Implications for the population history of humans. J Mol Evol 2002;54:28597.
  • 19
    Agostini HT, Ryschkewitsch CF, Baumhefner RW, Tourtellotte WW, Singer EJ, Komoly S, et al. Influence of JC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy. J Neurovirol 2000;6(Suppl 2):S1018.
  • 20
    Gheuens S, Fellay J, Goldstein DB, Koralnik IJ. Role of human leukocyte antigen class I alleles in progressive multifocal leukoencephalopathy. J Neurovirol 2010;16:417.
  • 21
    Zheng HY, Ikegaya H, Takasaka T, Matsushima-Ohno T, Sakurai M, Kanazawa I, et al. Characterization of the VP1 loop mutations widespread among JC polyomavirus isolates associated with progressive multifocal leukoencephalopathy. Biochem Biophys Res Commun 2005;333:9961002.
  • 22
    Zheng HY, Takasaka T, Noda K, Kanazawa A, Mori H, Kabuki T, et al. New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy. J Gen Virol 2005;86:203545.
  • 23
    Sunyaev SR, Lugovskoy A, Simon K, Gorelik L. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 2009;5:e1000368.
  • 24
    Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 2011;204:10314.
  • 25
    Grinnell BW, Padgett BL, Walker DL. Comparison of infectious JC virus DNAs cloned from human brain. J Virol 1983;45:299308.
  • 26
    Loeber G, Dorries K. DNA rearrangements in organ-specific variants of polyomavirus JC strain GS. J Virol 1988;62:17305.
  • 27
    Flaegstad T, Sundsfjord A, Arthur RR, Pedersen M, Traavik T, Subramani S. Amplification and sequencing of the control regions of BK and JC virus from human urine by polymerase chain reaction. Virology 1991;180:55360.
  • 28
    Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009;199:83746.
  • 29
    Martin JD, King DM, Slauch JM, Frisque RJ. Differences in regulatory sequences of naturally occurring JC virus variants. J Virol 1985;53:30611.
  • 30
    Tominaga T, Yogo Y, Kitamura T, Aso Y. Persistence of archetypal JC virus DNA in normal renal tissue derived from tumor-bearing patients. Virology 1992;186:73641.
  • 31
    Ault GS, Stoner GL. Human polyomavirus JC promoter/enhancer rearrangement patterns from progressive multifocal leukoencephalopathy brain are unique derivatives of a single archetypal structure. J Gen Virol 1993;74:1499507.
  • 32
    Gosert R, Kardas P, Major EO, Hirsch HH. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J Virol 2010;84:1044856.
  • 33
    Komagome R, Sawa H, Suzuki T, Suzuki Y, Tanaka S, Atwood WJ, et al. Oligosaccharides as receptors for JC virus. J Virol 2002;76:129923000.
  • 34
    Dugan AS, Gasparovic ML, Atwood WJ. Direct correlation between sialic acid binding and infection of cells by two human polyomaviruses (JC virus and BK virus). J Virol 2008;82:25604.
  • 35
    Querbes W, O'Hara BA, Williams G, Atwood WJ. Invasion of host cells by JC virus identifies a novel role for caveolae in endosomal sorting of noncaveolar ligands. J Virol 2006;80:940213.
  • 36
    Grinnell BW, Padgett BL, Walker DL. Distribution of nonintegrated DNA from JC papovavirus in organs of patients with progressive multifocal leukoencephalopathy. J Infect Dis 1983;147:66975.
  • 37
    Eash S, Tavares R, Stopa EG, Robbins SH, Brossay L, Atwood WJ. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. Am J Pathol 2004;164:41928.
  • 38
    Bayliss J, Karasoulos T, McLean CA. Frequency and large T (LT) sequence of JC polyomavirus DNA in oligodendrocytes, astrocytes and granular cells in non-PML brain. Brain Pathol 2012;22:32936.
  • 39
    Neu U, Maginnis MS, Palma AS, Stroh LJ, Nelson CD, Feizi T, et al. Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 2010;8:30919.
  • 40
    Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004;306:13803.
  • 41
    Chapagain ML, Sumibcay L, Gurjav U, Kaufusi PH, Kast RE, Nerurkar VR. Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol 2008;14:44854.
  • 42
    Chapagain ML, Verma S, Mercier F, Yanagihara R, Nerurkar VR. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology 2007;364:5563.
  • 43
    Li R, Sharma BN, Linder S, Gutteberg TJ, Hirsch HH, Rinaldo CH. Characteristics of polyomavirus BK (BKPyV) infection in primary human urothelial cells. Virology 2013;440:4150.
  • 44
    Tange S, Imai T, Nakanishi A. An SV40 mutant defective in VP4 expression exhibits a temperature-sensitive growth defect. Virus Res 2011;157:11620.
  • 45
    Sariyer IK, Merabova N, Patel PK, Knezevic T, Rosati A, Turco MC, et al. Bag3-induced autophagy is associated with degradation of JCV oncoprotein, T-Ag. PLoS ONE 2012;7:e45000.
  • 46
    Simmons DT. SV40 large T antigen functions in DNA replication and transformation. Adv Virus Res 2000;55:75134.
  • 47
    Bollag B, Kilpatrick LH, Tyagarajan SK, Tevethia MJ, Frisque RJ. JC virus T'135, T'136 and T'165 proteins interact with cellular p107 and p130 in vivo and influence viral transformation potential. J Neurovirol 2006;12:42842.
  • 48
    Khalili K, Gordon J, White MK. The polyomavirus, JCV and its involvement in human disease. Adv Exp Med Biol 2006;577:27487.
  • 49
    Orba Y, Suzuki T, Makino Y, Kubota K, Tanaka S, Kimura T, et al. Large T antigen promotes JC virus replication in G2-arrested cells by inducing ATM- and ATR-mediated G2 checkpoint signaling. J Biol Chem 2010;285:154454.
  • 50
    Bollag B, Hofstetter CA, Reviriego-Mendoza MM, Frisque RJ. JC virus small T antigen binds phosphatase PP2A and Rb family proteins and is required for efficient viral DNA replication activity. PLoS ONE 2010;5:e10606.
  • 51
    Wroblewska Z, Kennedy PG, Wellish MC, Lisak RP, Gilden DH. Demonstration of JC virus by immunofluorescence in multiple cell types in experimentally infected adult human brain cell cultures. J Neurol Sci 1982;54:18996.
  • 52
    Beckmann AM, Shah KV. Propagation and primary isolation of JCV and BKV in urinary epithelial cell cultures. Prog Clin Biol Res 1983;105:314.
  • 53
    Major EO, Miller AE, Mourrain P, Traub RG, de Widt E, Sever J. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A 1985;82:125761.
  • 54
    Assouline JG, Major EO. Human fetal Schwann cells support JC virus multiplication. J Virol 1991;65:10026.
  • 55
    Messam CA, Hou J, Gronostajski RM, Major EO. Lineage pathway of human brain progenitor cells identified by JC virus susceptibility. Ann Neurol 2003;53:63646.
  • 56
    Monaco MC, Maric D, Bandeian A, Leibovitch E, Yang W, Major EO. Progenitor-derived oligodendrocyte culture system from human fetal brain. J Vis Exp 2012; e4274. doi: 10.3791/4274.
  • 57
    Akatani K, Imai M, Kimura M, Nagashima K, Ikegami N. Propagation of JC virus in human neuroblastoma cell line IMR-32. J Med Virol 1994;43:139.
  • 58
    Safak M, Barrucco R, Darbinyan A, Okada Y, Nagashima K, Khalili K. Interaction of JC virus agno protein with T antigen modulates transcription and replication of the viral genome in glial cells. J Virol 2001;75:147686.
  • 59
    Nukuzuma S, Yogo Y, Guo J, Nukuzuma C, Itoh S, Shinohara T, et al. Establishment and characterization of a carrier cell culture producing high titres of polyoma JC virus. J Med Virol 1995;47:3707.
  • 60
    Hara K, Sugimoto C, Kitamura T, Aoki N, Taguchi F, Yogo Y. Archetype JC virus efficiently replicates in COS-7 cells, simian cells constitutively expressing simian virus 40 T antigen. J Virol 1998;72:533542.
  • 61
    Knowles WA, Sasnauskas K. Comparison of cell culture-grown JC virus (primary human fetal glial cells and the JCI cell line) and recombinant JCV VP1 as antigen for the detection of anti-JCV antibody by haemagglutination inhibition. J Virol Methods 2003;109:4754.
  • 62
    Broekema NM, Imperiale MJ. Efficient propagation of archetype BK and JC polyomaviruses. Virology 2012;422:23541.
  • 63
    Bollag B, Chuke WF, Frisque RJ. Hybrid genomes of the polyomaviruses JC virus, BK virus, and simian virus 40: Identification of sequences important for efficient transformation. J Virol 1989;63:86372.
  • 64
    Ferenczy MW, Johnson KR, Marshall LJ, Monaco MC, Major EO. Differentiation of human fetal multipotential neural progenitor cells to astrocytes reveals susceptibility factors for JC Virus. J Virol 2013;87:622131.
  • 65
    Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003;3:61123.
  • 66
    Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005;79:127786.
  • 67
    Hirsch HH. Of viruses and men: distinguishing infection, replication and disease. Future Virol 2006;1:6814.
  • 68
    Funk GF, Gosert R, Hirsch HH. Viral dynamics in transplant patients: implication for disease. Lancet Infect Dis 2007;7:46072.
  • 69
    Helantera I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH. Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010;24:33971.
  • 70
    Relman DA, Falkow S. Microbial Pathogenesis Section A. In: Mandell D, Bennett's E, editors. Principles and Practice of Infectious Diseases. 7th Edn. Philadelphia, Pennsylvania 19106: Elsevier Inc, 2010: 313.
  • 71
    Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003;1:1724.
  • 72
    Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295303.
  • 73
    Sindic CJ, Trebst C, Van Antwerpen MP, Frye S, Enzensberger W, Hunsmann G, et al. Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. J Neuroimmunol 1997;76:1004.
  • 74
    Cinque P, Dumoulin A, Hirsch HH. Diagnosis of polyomavirus infection, replication and disease. In: Jerome K, editor. Lennette's Laboratory Diagnosis of Viral Infections. New York: Informa Healthcare USA, Inc., 2009: 40124.
  • 75
    Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80:14308.
  • 76
    Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD, et al. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 2003;95:152230.
  • 77
    Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:11523.
  • 78
    Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003;84:1499504.
  • 79
    Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009;5:e1000363.
  • 80
    Bodaghi S, Comoli P, Boesch R, Azzi A, Gosert R, Leuenberger D, et al. Antibody Responses to Recombinant Polyomavirus BK Large T and VP1 Proteins in Pediatric Kidney Transplant Patients. J Clin Microbiol 2009;47:257785.
  • 81
    Antonsson A, Green AC, Mallitt KA, O'Rourke PK, Pawlita M, Waterboer T, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 2010;91:184953.
  • 82
    Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011;70:74250.
  • 83
    Major EO, Neel JV. The JC and BK human polyoma viruses appear to be recent introductions to some South American Indian tribes: there is no serological evidence of cross-reactivity with the simian polyoma virus SV40. Proc Natl Acad Sci U S A 1998;95:1552530.
  • 84
    Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 2006;577:1945.
  • 85
    Bofill-Mas S, Girones R. Role of the environment in the transmission of JC virus. J Neurovirol 2003;9(Suppl 1):548.
  • 86
    Bofill-Mas S, Formiga-Cruz M, Clemente-Casares P, Calafell F, Girones R. Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J Virol 2001;75:102909.
  • 87
    Egli A, Dumoulin A, Köhli S, Hirsch HH. Polyomavirus BK after kidney transplantation – Role of molecular and immunological markers. Trends Transplant 2009;3:85102.
  • 88
    Hamza IA, Jurzik L, Stang A, Sure K, Uberla K, Wilhelm M. Detection of human viruses in rivers of a densly-populated area in Germany using a virus adsorption elution method optimized for PCR analyses. Water Res 2009;43:265768.
  • 89
    Kitamura T, Kunitake T, Guo J, Tominaga T, Kawabe K, Yogo Y. Transmission of the human polyomavirus JC virus occurs both within the family and outside the family. J Clin Microbiol 1994;32:235963.
  • 90
    Kunitake T, Kitamura T, Guo J, Taguchi F, Kawabe K, Yogo Y. Parent-to-child transmission is relatively common in the spread of the human polyomavirus JC virus. J Clin Microbiol 1995;33:144851.
  • 91
    Boldorini R, Allegrini S, Miglio U, Paganotti A, Cocca N, Zaffaroni M, et al. Serological evidence of vertical transmission of JC and BK polyomaviruses in humans. J Gen Virol 2011;92:104450.
  • 92
    Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010;9:26472.
  • 93
    Khanna N, Wolbers M, Mueller NJ, Garzoni C, Du Pasquier RA, Fux CA, et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 2009;83:440411.
  • 94
    Matos A, Duque V, Beato S, da Silva JP, Major E, Melico-Silvestre A. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 2010;82:494504.
  • 95
    Leuenberger D, Andresen PA, Gosert R, Binggeli S, Strom EH, Bodaghi S, et al. Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol 2007;14:95968.
  • 96
    Wallen WC, London WT, Traub RG, Peterson KE, Witzel NL. Antibody responses to JC virus-associated antigens by tumor-bearing owl monkeys. Prog Clin Biol Res 1983;105:26170.
  • 97
    Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006;6:23143.
  • 98
    Paulson KG, Carter JJ, Johnson LG, Cahill KW, Iyer JG, Schrama D, et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res 2010;70:838897.
  • 99
    Sais G, Wyler S, Hudolin T, Banzola I, Mengus C, Bubendorf L, et al. Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia. J Virol 2012;86:846171.
  • 100
    Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 2000;38:1059.
  • 101
    Viscidi RP, Khanna N, Tan CS, Li X, Jacobson L, Clifford DB, et al. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011;53:7115.
  • 102
    Qu Q, Sawa H, Suzuki T, Semba S, Henmi C, Okada Y, et al. Nuclear entry mechanism of the human polyomavirus JC virus-like particle: role of importins and the nuclear pore complex. J Biol Chem 2004;279:2773542.
  • 103
    Chang D, Fung CY, Ou WC, Chao PC, Li SY, Wang M, et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol 1997;78:14359.
  • 104
    Randhawa P, Viscidi R, Carter JJ, Galloway DA, Culp TD, Huang C, et al. Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol 2009;90:6349.
  • 105
    Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, Wiendl H, et al. An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Mult Scler 2013. [Epub ahead of print].
  • 106
    Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, et al. JC virus antibody status underestimates infection rates. Ann Neurol 2013. doi: 10.1002/ana.23893. [Epub ahead of print].
  • 107
    Casadevall A, Pirofski LA. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 2006;91:144.
  • 108
    Pastrana DV, Brennan DC, Cuburu N, Storch GA, Viscidi RP, Randhawa PS, et al. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog 2012;8:e1002650.
  • 109
    Schowalter RM, Reinhold WC, Buck CB. Entry tropism of BK and Merkel Cell polyomaviruses in cell culture. PLoS ONE 2012;7:e42181.
  • 110
    Du Pasquier RA, Schmitz JE, Jean-Jacques J, Zheng Y, Gordon J, Khalili K, et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004;78:1020610.
  • 111
    Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004;127:19708.
  • 112
    Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, Zheng Y, et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 2002;168:499504.
  • 113
    Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, et al. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 2011;85:725663.
  • 114
    Du Pasquier RA, Autissier P, Zheng Y, Jean-Jacques J, Koralnik IJ. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 2005;19:206976.
  • 115
    Gasser O, Wolbers M, Steffen I, Hirsch HH, Battegay M, Hess C. Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphoma. AIDS 2007;21:16646.
  • 116
    Gasser O, Bihl FK, Wolbers M, Loggi E, Steffen I, Hirsch HH, et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4(+) T cell function irrespective of absolute CD4(+) T cell counts. PLoS Med 2007;4:e96.
  • 117
    Tan CS, Bord E, Broge TA Jr, Glotzbecker B, Mills H, Gheuens S, et al. Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr 2012;60:2448.
  • 118
    Du Pasquier RA, Stein MC, Lima MA, Dang X, Jean-Jacques J, Zheng Y, et al. JC virus induces a vigorous CD8+ cytotoxic T cell response in multiple sclerosis patients. J Neuroimmunol 2006;176:1816.
  • 119
    Hendel-Chavez H, de Goer de Herve MGGiannesini C, Mazet AA, Papeix C, Louapre C, et al. Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy. J Virol 2013;87:60559.
  • 120
    Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001;75:34837.
  • 121
    Du Pasquier RA, Kuroda MJ, Schmitz JE, Zheng Y, Martin K, Peyerl FW, et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 2003;77:1191826.
  • 122
    Krymskaya L, Sharma MC, Martinez J, Haq W, Huang EC, Limaye AP, et al. Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol 2005;79:111708.
  • 123
    Li J, Melenhorst J, Hensel N, Rezvani K, Sconocchia G, Kilical Y, et al. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J Gen Virol 2006;87:295160.
  • 124
    Provenzano M, Bracci L, Wyler S, Hudolin T, Sais G, Gosert R, et al. Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors. J Transl Med 2006;4:47.
  • 125
    Chen Y, Trofe J, Gordon J, Autissier P, Woodle ES, Koralnik IJ. BKV and JCV large T antigen-specific CD8(+) T cell response in HLA A*0201(+) kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J Clin Virol 2008;42:198202.
  • 126
    Jelcic I, Aly L, Binder TM, Jelcic I, Bofill-Mas S, Planas R, et al. T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol 2013;87:3393408.
  • 127
    Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, et al. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain 2011;134:2687702.
  • 128
    Coleman DV, Wolfendale MR, Daniel RA, Dhanjal NK, Gardner SD, Gibson PE, et al. A prospective study of human polyomavirus infection in pregnancy. J Infect Dis 1980;142:18.
  • 129
    Markowitz RB, Eaton BA, Kubik MF, Latorra D, McGregor JA, Dynan WS. BK virus and JC virus shed during pregnancy have predominantly archetypal regulatory regions. J Virol 1991;65:45159.
  • 130
    Markowitz RB, Thompson HC, Mueller JF, Cohen JA, Dynan WS. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects. J Infect Dis 1993;167:1320.
  • 131
    Matos A, Duque V, Luxo C, Melico-Silvestre A, Major EO. Individuals infected with JC polyomavirus do not present detectable JC virus DNA in oropharyngeal fluids. J Gen Virol 2012;93:6927.
  • 132
    Kitamura T, Aso Y, Kuniyoshi N, Hara K, Yogo Y. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis 1990;161:112833.
  • 133
    Vanchiere JA, White ZS, Butel JS. Detection of BK virus and simian virus 40 in the urine of healthy children. J Med Virol 2005;75:44754.
  • 134
    Knowles WA, Pillay D, Johnson MA, Hand JF, Brown DW. Prevalence of long-term BK and JC excretion in HIV-infected adults and lack of correlation with serological markers. J Med Virol 1999;59:4749.
  • 135
    Shah KV, Daniel RW, Strickler HD, Goedert JJ. Investigation of human urine for genomic sequences of the primate polyomaviruses simian virus 40, BK virus, and JC virus. J Infect Dis 1997;176:161821.
  • 136
    Daniel DC, Wortman MJ, Schiller RJ, Liu H, Gan L, Mellen JS, et al. Coordinate effects of human immunodeficiency virus type 1 protein Tat and cellular protein Puralpha on DNA replication initiated at the JC virus origin. J Gen Virol 2001;82:154353.
  • 137
    Tada H, Rappaport J, Lashgari M, Amini S, Wong-Staal F, Khalili K. Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci U S A 1990;87:347983.
  • 138
    Hirsch HH, Meylan PR, Zimmerli W, Iten A, Battegay M, Erb P. HIV-1-infected patients with focal neurologic signs: diagnostic role of PCR for Toxoplasma gondii, Epstein-Barr virus, and JC virus. Clin Microbiol Infect 1998;4:57784.
  • 139
    Kling CL, Wright AT, Katz SE, McClure GB, Gardner JS, Williams JT, et al. Dynamics of urinary polyomavirus shedding in healthy adult women. J Med Virol 2012;84:145963.
  • 140
    McClure GB, Gardner JS, Williams JT, Copeland CM, Sylvester SK, Garcea RL, et al. Dynamics of pregnancy-associated polyomavirus urinary excretion: a prospective longitudinal study. J Med Virol 2012;84:131222.
  • 141
    Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010;68:30410.
  • 142
    Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, et al. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol 2012;7:66572.
  • 143
    Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009;361:106774.
  • 144
    Delbue S, Guerini FR, Mancuso R, Caputo D, Mazziotti R, Saresella M, et al. JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls. J Neurovirol 2007;13:737.
  • 145
    Lonergan RM, Carr MJ, De Gascun CF, Costelloe LF, Waters A, Coughlan S, et al. Reactivation of BK polyomavirus in patients with multiple sclerosis receiving natalizumab therapy. J Neurovirol 2009;15:3519.
  • 146
    Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997;11:117.
  • 147
    Kuhle J, Gosert R, Buhler R, Derfuss T, Sutter R, Yaldizli O, et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011;77:20106.
  • 148
    Antinori A, Cingolani A, Lorenzini P, Giancola ML, Uccella I, Bossolasco S, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003;9(Suppl 1):4753.
  • 149
    Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005;43:41757.
  • 150
    Yiannoutsos CT, Major EO, Curfman B, Jensen PN, Gravell M, Hou J, et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999;45:81621.
  • 151
    Bossolasco S, Calori G, Moretti F, Boschini A, Bertelli D, Mena M, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005;40:73844.
  • 152
    De Luca A, Pezzotti P, Gasnault J, Cinque P, Berenguer J, Di Giambenedetto S, et al. Survival and neurological outcome with or without cidofovir (CDV) in AIDS-related progressive multifocal leukoencephalopathy (PML) on HAART: a multicohort analysis. J Neurovirol 2005;11:S16124.
  • 153
    Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, et al., for the Swiss HIV Cohort Study. Incidence and outcome of progressive multifocal leukoencephalopathy in 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009;48:145966.
  • 154
    Dumoulin A, Hirsch HH. Reevaluating and optimizing polyomavirus BK and JC real-time PCR assays to detect rare sequence polymorphisms. J Clin Microbiol 2011;49:13828.
  • 155
    Landry ML, Eid T, Bannykh S, Major E. False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing. J Clin Virol 2008;43:2479.
  • 156
    Ryschkewitsch CF, Jensen PN, Major EO. Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants. J Clin Virol 2013. doi. 10.1016/j.jcv.2013.03.009. [Epub ahead of print].
  • 157
    Grinnell BW, Martin JD, Padgett BL, Walker DL. Naturally occurring and passage-induced variation in the genome of JC virus. Prog Clin Biol Res 1983;105:6177.
  • 158
    Caldarelli-Stefano R, Vago L, Omodeo-Zorini E, Mediati M, Losciale L, Nebuloni M, et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neurovirol 1999;5:12533.
  • 159
    Newman JT, Frisque RJ. Detection of archetype and rearranged variants of JC virus in multiple tissues from a pediatric PML patient. J Med Virol 1997;52:24352.
  • 160
    Naess H, Glad S, Storstein A, Rinaldo CH, Mork SJ, Myhr KM, et al. Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report. BMC Neurol 2010;10:32.
  • 161
    Dang X, Wuthrich C, Gordon J, Sawa H, Koralnik IJ. JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS ONE 2012;7:e35793.
  • 162
    Dang X, Vidal JE, Oliveira AC, Simpson DM, Morgello S, Hecht JH, et al. JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol 2012;93:17583.
  • 163
    Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali RK, Munivenkatappa R, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation 2007;84:32330.
  • 164
    Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958;81:93111.
  • 165
    Arkema EV, van Vollenhoven RF, Askling J. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis 2012;71:18657.
  • 166
    Bharat A, Xie F, Baddley JW, Beukelman T, Chen L, Calabrese L, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken) 2012;64:6125.
  • 167
    Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009;60:37615.
  • 168
    Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009;199:7783.
  • 169
    Mateen FJ, Muralidharan R, Carone M, van de Beek D, Harrison DM, Aksamit AJ, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011;70:30522.
  • 170
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:187080.
  • 171
    Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:483440.
  • 172
    Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:115664.
  • 173
    Schwab N, Ulzheimer JC, Fox RJ, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, et al. Fatal PML associated with efalizumab therapy: insights into integrin alphaLbeta2 in JC virus control. Neurology 2012;78:45867.
  • 174
    van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368:16589. discussion 465.
  • 175
    Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:16578.
  • 176
    Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med 2013;368:165961.
  • 177
    Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 2010;81:24754.
  • 178
    Delgado-Alvarado M, Sedano MJ, Gonzalez-Quintanilla V, de Lucas EM, Polo JM, Berciano J. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci 2013;327:759.
  • 179
    Moloney F, Fernandez D, Harrington H. Progressive multifocal leucoencephalopathy in a patient with idiopathic CD4+ lymphocytopenia. Ir Med J 2012;105:845.
  • 180
    Puri V, Chaudhry N, Gulati P, Patel N, Tatke M, Sinha S. Progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+T lymphocytopenia. Neurol India 2010;58:11821.
  • 181
    Melzi S, Bonfanti P, Carenzi L, Faggion I, Resta M, Resta F, et al. Progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ cells deficit. Clin Ter 2008;159:3257.
  • 182
    Kokubun N, Ishihara T, Nishibayashi M, Ikeda S, Nagashima K, Hirata K. Progressive multifocal leukoencephalopathy with idiopathic CD4 positive T-lymphocytepenia mimicking a low grade glioma on proton MR spectroscopy. A case report. Rinsho Shinkeigaku 2005;45:6638.
  • 183
    Haider S, Nafziger D, Gutierrez JA, Brar I, Mateo N, Fogle J. Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases. Clin Infect Dis 2000;31:E202.
  • 184
    Weber T, Trebst C, Frye S, Cinque P, Vago L, Sindic CJ, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997;176:2504.
  • 185
    Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009;73:15518.
  • 186
    Warnke C, Ramanujam R, Plavina T, Bergstrom T, Goelz S, Subramanyam M, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 2013. doi: 10.1136/jnnp-2012-304332. [Epub ahead of print].
  • 187
    Chowdhury M, Taylor JP, Chang CF, Rappaport J, Khalili K. Evidence that a sequence similar to TAR is important for induction of the JC virus late promoter by human immunodeficiency virus type 1 Tat. J Virol 1992;66:735561.
  • 188
    Del Valle L, Croul S, Morgello S, Amini S, Rappaport J, Khalili K. Detection of HIV-1 Tat and JCV capsid protein, VP1, in AIDS brain with progressive multifocal leukoencephalopathy. J Neurovirol 2000;6:2218.
  • 189
    Del Valle L, Gordon J, Assimakopoulou M, Enam S, Geddes JF, Varakis JN, et al. Detection of JC virus DNA sequences and expression of the viral regulatory protein T-antigen in tumors of the central nervous system. Cancer Res 2001;61:428793.
  • 190
    Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008;194:15364.
  • 191
    Marshall LJ, Moore LD, Mirsky MM, Major EO. JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes. J Gen Virol 2012;93:65161.
  • 192
    Marshall LJ, Dunham L, Major EO. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol 2010;91:304252.
  • 193
    Dubois V, Moret H, Lafon ME, Janvresse CB, Dussaix E, Icart J, et al. Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study. J Neurovirol 1998;4:53944.
  • 194
    Dubois V, Lafon ME, Ragnaud JM, Pellegrin JL, Damasio F, Baudouin C, et al. Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients. AIDS 1996;10:3538.
  • 195
    Tan CS, Ellis LC, Wuthrich C, Ngo L, Broge TA Jr, Saint-Aubyn J, et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol 2010;84:92009.
  • 196
    Bayliss J, Karasoulos T, McLean CA. Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy. J Infect Dis 2013;207:1336.
  • 197
    Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol 2001;7:2807.
  • 198
    Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, et al. Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain. Clin Microbiol Rev 2012;25:471506.
  • 199
    Nakamichi K, Kishida S, Tanaka K, Suganuma A, Sano Y, Sano H, et al. Sequential changes in the non-coding control region sequences of JC polyomaviruses from the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. Arch Virol 2013;158:63950.
  • 200
    Nukuzuma S, Kameoka M, Sugiura S, Nakamichi K, Nukuzuma C, Miyoshi I, et al. Exogenous human immunodeficiency virus-1 protein, Tat, enhances replication of JC virus efficiently in neuroblastoma cell lines. J Med Virol 2012;84:55561.
  • 201
    Chapagain ML, Nerurkar VR. Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 2010;202:18491.
  • 202
    Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988;318:3015.
  • 203
    Mazlo M, Tariska I. Morphological demonstration of the first phase of polyomavirus replication in oligodendroglia cells of human brain in progressive multifocal leukoencephalopathy (PML). Acta Neuropathol 1980;49:13343.
  • 204
    Mazlo M, Tariska I. Are astrocytes infected in progressive multifocal leukoencephalopathy (PML)? Acta Neuropathol 1982;56:4551.
  • 205
    Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006;66:2624.
  • 206
    Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoen-cephalopathy. Ann Neurol 2012;72:77987.
  • 207
    Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:10817.
  • 208
    Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002;35:12507.
  • 209
    Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003;9(Suppl 1):2531.
  • 210
    Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004;38:115966.
  • 211
    Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011;77:10617.
  • 212
    Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003;9(Suppl 1):8892.
  • 213
    Marzocchetti A, Sanguinetti M, Giambenedetto SD, Cingolani A, Fadda G, Cauda R, et al. Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis. J Neurovirol 2007;13:33846.
  • 214
    Crowder CD, Gyure KA, Drachenberg CB, Werner J, Morales RE, Hirsch HH, et al. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant 2005;5:11518.
  • 215
    Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sorensen PS. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. Mult Scler 2013. [Epub ahead of print].
  • 216
    Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:74558.
  • 217
    Balduzzi A, Lucchini G, Hirsch HH, Basso S, Cioni M, Rovelli A, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant 2011;46:98792.
  • 218
    Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998;338:134551.
  • 219
    De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. Aids 2008;22:175967.
  • 220
    Pohlmann C, Hochauf K, Rollig C, Schetelig J, Wunderlich O, Bandt D, et al. Chlorpromazine combined with cidofovir for treatment of a patient suffering from progressive multifocal leukoencephalopathy. Intervirology 2007;50:4127.
  • 221
    Lanzafame M, Ferrari S, Lattuada E, Corsini F, Deganello R, Vento S, et al. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med 2009;17:357.
  • 222
    Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009;53:18409.
  • 223
    Park JH, Ryoo S, Noh HJ, Seo JM, Kang HH, Shin JS, et al. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep Neurol 2011;3:25862.
  • 224
    Ripellino P, Comi C, Mula M, Varrasi C, Conconi A, Stecco A, et al. Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Rep 2011. doi: 10.1136/bcr.11.2010.3549.
  • 225
    Gosert R, Rinaldo CH, Wernli M, Major EO, Hirsch HH. CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes. Antimicrob Agents Chemother 2011;55:212936.
  • 226
    Patel A, Patel J, Ikwuagwu J. Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 2010;65:248992.
  • 227
    Du Pasquier RA, Corey S, Margolin DH, Williams K, Pfister LA, De Girolami U, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003;61:77582.
  • 228
    Koralnik IJ, Wuthrich C, Dang X, Rottnek M, Gurtman A, Simpson D, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005;57:57680.
  • 229
    Dang X, Koralnik IJ. A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene. J Gen Virol 2006;87:25337.
  • 230
    Roux D, Bouldouyre MA, Mercier-Delarue S, Seilhean D, Zagdanski AM, Delaugerre C, et al. JC virus variant associated with cerebellar atrophy in a patient with AIDS. J Clin Microbiol 2011;49:21969.
  • 231
    Wuthrich C, Cheng YM, Joseph JT, Kesari S, Beckwith C, Stopa E, et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2009;68:1525.
  • 232
    Granot R, Lawrence R, Barnett M, Masters L, Rodriguez M, Theocharous C, et al. What lies beneath the tent? JC-virus cerebellar granule cell neuronopathy complicating sarcoidosis. J Clin Neurosci 2009;16:10912.
  • 233
    Wuthrich C, Dang X, Westmoreland S, McKay J, Maheshwari A, Anderson MP, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009;65:7428.
  • 234
    Myhre MR, Olsen GH, Gosert R, Hirsch HH, Rinaldo CH. Clinical polyomavirus BK variants with agnogene deletion are non-functional but rescued by trans-complementation. Virology 2010;398:1220.
  • 235
    Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Bonington A. BKV-DNA and JCV-DNA in CSF of patients with suspected meningitis or encephalitis. Infection 2003;31:3748.
  • 236
    Blake K, Pillay D, Knowles W, Brown DW, Griffiths PD, Taylor B. JC virus associated meningoencephalitis in an immunocompetent girl. Arch Dis Child 1992;67:9567.
  • 237
    Viallard JF, Ellie E, Lazaro E, Lafon ME, Pellegrin JL. JC virus meningitis in a patient with systemic lupus erythematosus. Lupus 2005;14:9646.
  • 238
    Kazory A, Ducloux D, Chalopin JM, Angonin R, Fontaniere B, Moret H. The first case of JC virus allograft nephropathy. Transplantation 2003;76:16535.
  • 239
    Pires EP, Bernardino-Vallinoto CV, Alves DM, Migone SR, Machado LF, Ishak MO, et al. Prevalence of infection by JC and BK polyomaviruses in kidney transplant recipients and patients with chronic renal disease. Transpl Infect Dis 2011;13:6337.
  • 240
    Mengelle C, Kamar N, Mansuy JM, Sandres-Saune K, Legrand-Abravanel F, Miedouge M, et al. JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France. J Med Virol 2011;83:1326.
  • 241
    Randhawa P, Baksh F, Aoki N, Tschirhart D, Finkelstein S. JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. Transplantation 2001;71:13003.
  • 242
    Wen MC, Wang CL, Wang M, Cheng CH, Wu MJ, Chen CH, et al. Association of JC virus with tubulointerstitial nephritis in a renal allograft recipient. J Med Virol 2004;72:6758.
  • 243
    Gosert R, Rinaldo CH, Funk GA, Egli A, Ramos E, Drachenberg CB, et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008;205:84152.
  • 244
    Kantarci G, Eren Z, Demirag A, Dogan I, Cakalagaoglu F, Yilmaz G. JC virus-associated nephropathy in a renal transplant recipient and comparative analysis of previous cases. Transpl Infect Dis 2011;13:8992.
  • 245
    Delbue S, Ferraresso M, Ghio L, Carloni C, Carluccio S, Belingheri M, et al. A review on JC virus infection in kidney transplant recipients. Clin Dev Immunol 2013;2013:926391.
  • 246
    Cheng XS, Bohl DL, Storch GA, Ryschkewitsch C, Gaudreault-Keener M, Major EO, et al. Inhibitory interactions between BK and JC virus among kidney transplant recipients. J Am Soc Nephrol 2011;22:82531.
  • 247
    Boldorini R, Omodeo-Zorini E, Nebuloni M, Benigni E, Vago L, Ferri A, et al. Lytic JC virus infection in the kidneys of AIDS subjects. Mod Pathol 2003;16:3542.
  • 248
    Rencic A, Gordon J, Otte J, Curtis M, Kovatich A, Zoltick P, et al. Detection of JC virus DNA sequence and expression of the viral oncoprotein, tumor antigen, in brain of immunocompetent patient with oligoastrocytoma. Proc Natl Acad Sci U S A 1996;93:73527.
  • 249
    Caldarelli-Stefano R, Boldorini R, Monga G, Meraviglia E, Zorini EO, Ferrante P. JC virus in human glial-derived tumors. Hum Pathol 2000;31:3945.
  • 250
    Del Valle L, Enam S, Lara C, Ortiz-Hidalgo C, Katsetos CD, Khalili K. Detection of JC polyomavirus DNA sequences and cellular localization of T-antigen and agnoprotein in oligodendrogliomas. Clin Cancer Res 2002;8:333240.
  • 251
    Krynska B, Del Valle L, Croul S, Gordon J, Katsetos CD, Carbone M, et al. Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc Natl Acad Sci U S A 1999;96:1151924.
  • 252
    Del Valle L, Enam S, Lara C, Miklossy J, Khalili K, Gordon J. Primary central nervous system lymphoma expressing the human neurotropic polyomavirus, JC virus, genome. J Virol 2004;78:34629.
  • 253
    Rollison DE, Engels EA, Halsey NA, Shah KV, Viscidi RP, Helzlsouer KJ. Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2006;15:54350.
  • 254
    Nosho K, Yamamoto H, Takahashi T, Mikami M, Hizaki K, Maehata T, et al. Correlation of laterally spreading type and JC virus with methylator phenotype status in colorectal adenoma. Hum Pathol 2008;39:76775.
  • 255
    Nosho K, Shima K, Kure S, Irahara N, Baba Y, Chen L, et al. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia 2009;11:8795.
  • 256
    Yamaoka S, Yamamoto H, Nosho K, Taniguchi H, Adachi Y, Sasaki S, et al. Genetic and epigenetic characteristics of gastric cancers with JC virus T-antigen. World J Gastroenterol 2009;15:557985.
  • 257
    Laghi L, Randolph AE, Chauhan DP, Marra G, Major EO, Neel JV, et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci U S A 1999;96:74849.
  • 258
    Ricciardiello L, Laghi L, Ramamirtham P, Chang CL, Chang DK, Randolph AE, et al. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology 2000;119:122835.
  • 259
    Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011;17:145262.
  • 260
    Ramamoorthy S, Devaraj B, Miyai K, Luo L, Liu YT, Boland CR, et al. John Cunningham virus T-antigen expression in anal carcinoma. Cancer 2010;11:237985.
  • 261
    Rollison DE, Utaipat U, Ryschkewitsch C, Hou J, Goldthwaite P, Daniel R, et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int J Cancer 2005;113:76974.
  • 262
    Hirsch HH, Elzi L, Buitrago C, Battegay M. Acute neurologic worsening of progressive mulitfocal leukoencephalopathy after starting HAART. J Neurovirol 2004;10:712.